Qualys reports the discovery by their threat research unit of vulnerabilities in the Linux AppArmor system used by SUSE, Debian, Ubuntu, and ...

OpenAI announced Thursday that it has entered into an agreement to acquire Astral, the company behind popular open source Python development tools such as uv, Ruff, and ty, and integrate the company ...

SerpApi alleges it’s just doing ‘what Google does to everyone else.’ SerpApi alleges it’s just doing ‘what Google does to everyone else.’ is a news writer who covers the streaming wars, consumer tech, ...

The viral virtual assistant OpenClaw—formerly known as Moltbot, and before that Clawdbot—is a symbol of a broader revolution underway that could fundamentally alter how the internet functions. Instead ...

TrendScope is a full-stack (Next.js/FastAPI) web application that relies on Selenium web-scraping to extract the latest trends from X (formerly known as Twitter). With the use of multiple headers and ...

Google, Reddit Complaints Allege Texas Web-Scraping Service Violates DMCA Google alleges SerpApi is a “parasitic” enterprise. SerpApi maintains its services are protected by the First Amendment and ...

Google claims SerpApi built tools specifically to bypass its new "SearchGuard" defense system. The lawsuit targets the "trafficking" of circumvention tools under the DMCA, not just scraping. Google is ...

Dec 19 (Reuters) - Google (GOOGL.O), opens new tab on Friday sued a Texas company that "scrapes" data from online search results, alleging it uses hundreds of millions of fake Google search requests ...

SerpApi says it can deliver Google search results for use by AI tools, but Google claims it’s illegally evading bot-blockers to steal copyrighted content. SerpApi says it can deliver Google search ...

Generative AI companies and websites are locked in a bitter struggle over automated scraping. The AI companies are increasingly aggressive about downloading pages for use as training data; the ...

Colorectal cancer (CRC) remains a major global health challenge, with limited immunotherapy efficacy in microsatellite stable (MSS) tumors that comprise ~85% of cases. The p53 tumor suppressor pathway ...